This content is from: Premium

Valeant’s Winners and Losers

The troubled drugmaker takes another plunge as it reduces guidance. Here’s a quick survey of the firms that are taking a bath and those that look like geniuses.

Was Tuesday capitulation day for shareholders of Valeant Pharmaceuticals International, which lost nearly half its value after cutting its revenue and earnings guidance for the rest of the year amid fears that it may default on its debt? Was this the day its longtime bulls finally surrendered and liquidated their

To continue reading, subscribe now to Premium Journalism. Already a subscriber? Login.

Related Content